Monte Rosa Therapeutics
GLUE
81 hedge funds and large institutions have $264M invested in Monte Rosa Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 11 reducing their positions, and 7 closing their positions.
442% more call options, than puts
Call options by funds: $895K | Put options by funds: $165K
273% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
54% more capital invested
Capital invested by funds: $171M → $264M (+$92.2M)
9% more funds holding
Funds holding: 74 → 81 (+7)
6.12% more ownership
Funds ownership: 74.96% → 81.07% (+6.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$6.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.15M |
| 3 |
BlackRock
New York
|
+$2.73M |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$2.15M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.3M |
| 2 |
CC
Casdin Capital
New York
|
-$883K |
| 3 |
Jane Street
New York
|
-$257K |
| 4 |
SP
Sarasin & Partners
London,
United Kingdom
|
-$243K |
| 5 |
Renaissance Technologies
New York
|
-$182K |
GLUE Hedge Fund Activity: Q3 2024 in Review
81 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2024, worth a combined $264M — up 54% from $171M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GLUE positions and 7 closed out — a net gain of 7 holders — while 41 added to existing stakes and 11 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $6.34M. The largest seller was Sphera Funds Management, cutting an estimated $1.3M.
- 81 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2024, up from 74 in Q2 2024.
- Funds reported $264M of Monte Rosa Therapeutics stock for Q3 2024, up 54% quarter-over-quarter.
- 14 funds opened new Monte Rosa Therapeutics positions in Q3 2024 and 7 closed out, a net change of +7 holders.
- The largest Monte Rosa Therapeutics buyer in Q3 2024 was Avoro Capital Advisors, an estimated $6.34M added.
- The largest Monte Rosa Therapeutics seller in Q3 2024 was Sphera Funds Management, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2024.